ADIL

Adial Pharmaceuticals, Inc. (ADIL) | Rumor.io

Adial Pharmaceuticals

ADIL

Attention (50-day avg)0%

Attention rank (50-day avg)#4,042

Bullish sentiment (50-day avg)0%

Price to earnings ratio0.01

Market capitalization11.9M

Earnings per share-17.7

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8M

Social

What share of all stock conversation is about ADIL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jun 12

Adial Pharmaceuticals ($ADIL) is expected to make a big move after a potential short squeeze, with some traders anticipating a price increase to $3-5.
The stock's chart is building on recent strength, with a key level of support at $2.50, and some traders are betting on a continued upward trend.
There have been reports of insider trading and a potential private placement, which some traders believe could lead to a significant increase in the stock's price.

Generated by AI

Sentiment

Of the messages about ADIL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	76.51% -11.81
Bearish	—	—	—	23.49% +11.81

Bullish· Jun 11

$ADIL has the potential for a significant price increase, with some analysts predicting a 1,000% return in a day due to its low float and high short interest.
The company's recent news and good numbers on paper are expected to drive the stock price higher, with some users predicting a price target of $11+.
$ADIL is considered a strong candidate for a short squeeze, with a low market cap and a recent history of large price movements, making it a potentially lucrative trade for bulls.

Bearish· Jun 11

$ADIL has seen significant price swings, including a 125% increase followed by a crash within 18 minutes, making technical analysis and chart reading less effective in this market.
Adial Pharmaceuticals' warrants are priced under $3, with millions of them available, which may deter investors from taking a position in the company.
The stock has been prone to sudden and significant price drops, with some investors experiencing losses as high as 40% in a short period of time.

Generated by AI

Topics

Of the messages about ADIL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	2.55%
Announcements	—	—	—	75.8%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	21.66%

Announcements· Mar 3

Adial Pharmaceuticals, Inc. ($ADIL) has signed an exclusive AD04 agreement with Molteni Farmaceutici for Europe, anticipating nearly $60 million in potential royalties and milestones.
The deal could extend the patent filing for AD04, potentially extending the license expiration date from 2031 to 2045 if granted.
Adial Pharmaceuticals has secured manufacturing agreements with Thermo as part of the exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe.

Technical Analysis· Jun 26

$ADIL is oversold and due for a bounce, with a possible target of $0.5+ if it breaks through $0.32.
The stock is forming a bullish pattern and has a clean coil on the 1m and 5m charts, with volume building and a healthy tape.
The technicals are aligning for a breakout, with the MACD turning bullish, MFI > 80, ADX confirming trend strength, and a break above EMA and VWAP, with targets of $0.356 → $0.47 and beyond.

Generated by AI

Community

Of the messages about ADIL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	2.45%
Newcomers	—	—	—	97.55%

Regulars· Aug 6

Adial Pharmaceuticals has completed a successful FDA meeting for its EOP2 trial, a significant milestone in the development of its lead asset.
The company's non-abstinence-based approach to reducing alcohol use is gaining traction, as a recent report highlights the effectiveness of cutting back on alcohol compared to total abstinence.
Adial Pharmaceuticals' mission to reduce alcohol use through a non-abstinence-based approach aligns with the growing trend of harm reduction strategies in the treatment of addiction.

Newcomers· Jul 30

The company is awaiting an FDA meeting on July 29 to discuss Phase 3 trials for its addiction treatment, AD04.
The stock's price has been impacted by the uncertainty surrounding the FDA meeting, with some traders anticipating a potential spike or rejection.
The company's Phase 3 trial design and potential for precision medicine have been cited as reasons for optimism, with some analysts predicting a significant increase in the stock's value.

Generated by AI

GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company. The option award has an exercise price of $5.76 per share, the closing price of the Company’s common stock on August 19, 2026, the effective date of grant and has a ten-

1mo agoYahoo Finance

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline Closed initial $32 million tranche, including the conversion of notes, of an up to $64 million private placement from biotech specialist investors GLEN ALLEN, Va., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”) today provided a business update and

1mo agoYahoo Finance

Also Discussed

Investors talking about ADIL also mention

#	Name	Attention
1	MRIN - Marin Software Incorporated	——
2	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
3	Planet Green Holdings Corp.PLAG	0%new
4	Uxin Ltd. ADRUXIN	0%0
5	Hoth Therapeutics Inc.HOTH	0%new
6	Bio-Path Holdings Inc.BPTH	0%0
7	Milestone Scientific Inc.MLSS	0%+0
8	MINM - Minim, Inc.	——
9	AIH - Aesthetic Medical International Holdings Group Limited	——
10	Stabilis Solutions Inc.SLNG	0%0

Adial Pharmaceuticals, Inc.

Healthcare
Biotechnology

Adial Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing prescription therapies for addiction and related disorders, with a current emphasis on alcohol use disorder. Its lead program, AD04, is a genetically targeted serotonin-3 receptor antagonist being developed to help reduce heavy drinking in patients with specific biomarker profiles. The company also works on additional drug candidates aimed at non-opioid pain reduction and other medical conditions. Adial Pharmaceuticals, Inc. operates as a clinical-stage developer, concentrating on translating research into regulated therapeutic products through clinical studies and product development. The company’s current pipeline reflects a precision-medicine approach that seeks to match treatments with defined patient groups, placing it within the specialized segment of neuroscience and addiction-focused biopharmaceuticals.

Website

Location

4870 Sadler Road

Glen Allen, VA, 23060

United States

Social

What share of all stock conversation is about ADIL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jun 12

Adial Pharmaceuticals ($ADIL) is expected to make a big move after a potential short squeeze, with some traders anticipating a price increase to $3-5.
The stock's chart is building on recent strength, with a key level of support at $2.50, and some traders are betting on a continued upward trend.
There have been reports of insider trading and a potential private placement, which some traders believe could lead to a significant increase in the stock's price.

Generated by AI

Sentiment

Of the messages about ADIL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	76.51% -11.81
Bearish	—	—	—	23.49% +11.81

Bullish· Jun 11

$ADIL has the potential for a significant price increase, with some analysts predicting a 1,000% return in a day due to its low float and high short interest.
The company's recent news and good numbers on paper are expected to drive the stock price higher, with some users predicting a price target of $11+.
$ADIL is considered a strong candidate for a short squeeze, with a low market cap and a recent history of large price movements, making it a potentially lucrative trade for bulls.

Bearish· Jun 11

$ADIL has seen significant price swings, including a 125% increase followed by a crash within 18 minutes, making technical analysis and chart reading less effective in this market.
Adial Pharmaceuticals' warrants are priced under $3, with millions of them available, which may deter investors from taking a position in the company.
The stock has been prone to sudden and significant price drops, with some investors experiencing losses as high as 40% in a short period of time.

Generated by AI

Topics

Of the messages about ADIL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	2.55%
Announcements	—	—	—	75.8%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	21.66%

Announcements· Mar 3

Adial Pharmaceuticals, Inc. ($ADIL) has signed an exclusive AD04 agreement with Molteni Farmaceutici for Europe, anticipating nearly $60 million in potential royalties and milestones.
The deal could extend the patent filing for AD04, potentially extending the license expiration date from 2031 to 2045 if granted.
Adial Pharmaceuticals has secured manufacturing agreements with Thermo as part of the exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe.

Technical Analysis· Jun 26

$ADIL is oversold and due for a bounce, with a possible target of $0.5+ if it breaks through $0.32.
The stock is forming a bullish pattern and has a clean coil on the 1m and 5m charts, with volume building and a healthy tape.
The technicals are aligning for a breakout, with the MACD turning bullish, MFI > 80, ADX confirming trend strength, and a break above EMA and VWAP, with targets of $0.356 → $0.47 and beyond.

Generated by AI

Community

Of the messages about ADIL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	2.45%
Newcomers	—	—	—	97.55%

Regulars· Aug 6

Adial Pharmaceuticals has completed a successful FDA meeting for its EOP2 trial, a significant milestone in the development of its lead asset.
The company's non-abstinence-based approach to reducing alcohol use is gaining traction, as a recent report highlights the effectiveness of cutting back on alcohol compared to total abstinence.
Adial Pharmaceuticals' mission to reduce alcohol use through a non-abstinence-based approach aligns with the growing trend of harm reduction strategies in the treatment of addiction.

Newcomers· Jul 30

The company is awaiting an FDA meeting on July 29 to discuss Phase 3 trials for its addiction treatment, AD04.
The stock's price has been impacted by the uncertainty surrounding the FDA meeting, with some traders anticipating a potential spike or rejection.
The company's Phase 3 trial design and potential for precision medicine have been cited as reasons for optimism, with some analysts predicting a significant increase in the stock's value.

Generated by AI

Adial Pharmaceuticals

Social

Jun 12

Sentiment

Bullish· Jun 11

Bearish· Jun 11

Topics

Announcements· Mar 3

Technical Analysis· Jun 26

Community

Regulars· Aug 6

Newcomers· Jul 30

News

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

Adial Pharmaceuticals plans leadership changes tied to annual meeting vote

Coastlands Capital buys $8,690 of Adial Pharmaceuticals stock

10% owner Coastlands Capital buys $32,637 in Adial Pharmaceuticals

Also Discussed

Adial Pharmaceuticals, Inc.

Company Information

Location

News

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

Adial Pharmaceuticals plans leadership changes tied to annual meeting vote

Coastlands Capital buys $8,690 of Adial Pharmaceuticals stock

10% owner Coastlands Capital buys $32,637 in Adial Pharmaceuticals

Also Discussed

Social

Jun 12

Sentiment

Bullish· Jun 11

Bearish· Jun 11

Topics

Announcements· Mar 3

Technical Analysis· Jun 26

Community

Regulars· Aug 6

Newcomers· Jul 30